(Q37679940)

21 August 2017

1 reference

title

Emerging drugs for pulmonary hypertension (English)

1 reference

21 August 2017

arterial hypertension

0 references

author name string

Reda E Girgis

series ordinal

1

1 reference

PubMed ID

20095920

21 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Emerging Drugs

21 August 2017

1 reference

21 August 2017

15

1 reference

21 August 2017

1

1 reference

21 August 2017

71-85

1 reference

Diagnosis and assessment of pulmonary arterial hypertension.

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Updated clinical classification of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Pathology of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Cellular and molecular basis of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Inflammation, growth factors, and pulmonary vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Genetics and genomics of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Pulmonary arterial hypertension in France: results from a national registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

A USA-based registry for pulmonary arterial hypertension: 1982-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Evaluating health-related quality of life, work ability, and disability in pulmonary arterial hypertension: an unmet need

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American Co

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Inhaled iloprost for severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Role of endothelin receptors on basal and endothelin-1-stimulated lung myofibroblast proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Sitaxsentan therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Tadalafil therapy for pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Signaling molecules in nonfamilial pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Beraprost therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

A long-acting and highly selective prostacyclin receptor agonist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), ameliorates rat pulmonary hypertension with unique relaxant responses of its act

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

NO-independent, haem-dependent soluble guanylate cyclase stimulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Cicletanine stimulates nitric oxide release and scavenges superoxide in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Cicletanine for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Tetrahydrobiopterin and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

L-Citrulline ameliorates chronic hypoxia-induced pulmonary hypertension in newborn piglets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Reversal of experimental pulmonary hypertension by PDGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Imatinib for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Novel approaches to the pharmacotherapy of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Anorectic drugs and pulmonary hypertension from the bedside to the bench

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Therapeutic targets in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Simvastatin and sildenafil combine to attenuate pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

VPAC and PAC receptors: From ligands to function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903551271

10.1517/14728210903551271

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

20095920